{"id":477996,"date":"2021-04-19T08:33:20","date_gmt":"2021-04-19T12:33:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/"},"modified":"2021-04-19T08:33:20","modified_gmt":"2021-04-19T12:33:20","slug":"allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/","title":{"rendered":"Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR\u2122 Candidate, for the Treatment of Patients with Relapsed\/Refractory Multiple Myeloma"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li>TurboCAR Technology Allows a Programmable Cytokine Signaling to Potentially Control T Cell Exhaustion and Improve Function and Potency of AlloCAR T\u2122\u00a0Cells<\/li>\n<li>Phase 1 IGNITE Trial Expected to Begin in Mid-2021<\/li>\n<li>ALLO-605 is One of Allogene\u2019s Three Strategies to Target BCMA for the Treatment of Patients with Multiple Myeloma<\/li>\n<\/ul>\n<p>SOUTH SAN FRANCISCO, Calif., April  19, 2021  (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) therapies for cancer today announced that the\u00a0U.S. Food &amp; Drug Administration\u00a0(FDA) has cleared an Investigational New Drug (IND) application to study ALLO-605 for the treatment of patients with relapsed or refractory multiple myeloma. ALLO-605 is part of the company\u2019s multi-faceted strategy to develop an allogeneic CAR T therapy targeting BCMA for the treatment of multiple myeloma. The Phase I IGNITE trial will evaluate escalating doses of ALLO-605 beginning in mid-2021.<\/p>\n<p>ALLO-605 is the Company\u2019s first TurboCAR\u2122 clinical candidate. TurboCAR is a proprietary, next generation platform technology based on a programmable cytokine signaling, designed to control T cell exhaustion, and improve T cell function and potency to reduce dosing requirement of AlloCAR T\u2122\u00a0cells. These properties may enable CAR T therapy to succeed in more difficult to treat hematologic malignancies and solid tumors.<\/p>\n<p>\u201cClearance of the ALLO-605 IND marks the beginning of the third stage of our three-pronged strategy targeting BCMA for relapsed\/refractory multiple myeloma,\u201d said Rafael Amado, M.D., Executive Vice President of Research &amp; Development and Chief Medical Officer of Allogene. \u201cWe look forward to initiating the IGNITE trial and are excited to advance a new technology platform that has the potential to transform the field of engineered T cell therapy.\u201d<\/p>\n<p>As part of the Company\u2019s anti-BCMA strategy, Allogene continues to enroll relapsed\/refractory multiple myeloma patients in the Phase 1 UNIVERSAL study with the goal of optimizing dosing of ALLO-715 and ALLO-647. Allogene in collaboration with SpringWorks Therapeutics is also evaluating ALLO-715 in combination with the investigational gamma secretase inhibitor, nirogacestat, for the treatment of multiple myeloma.<\/p>\n<p>\n        <strong>About ALLO-605<\/strong><br \/>\n        <br \/>ALLO-605 is a next-generation AlloCAR T investigational therapy that targets the B-cell maturation antigen (BCMA) for the treatment of patients with relapsed\/refractory multiple myeloma and other BCMA-positive malignancies. ALLO-605 incorporates Allogene\u2019s proprietary TurboCAR technology, which allows for cytokine activation signaling to be engineered selectively into CAR T cells. Preclinical results with ALLO-605 were presented at the American Society of Hematology (ASH) annual meeting in December 2020.<\/p>\n<p>\n        <strong>About\u00a0Allogene Therapeutics<\/strong><br \/>\n        <br \/>Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T\u2122) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of \u201coff-the-shelf\u201d CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.<\/p>\n<p>\n        <strong>Cautionary Note on Forward-Looking Statements <\/strong><br \/>\n        <br \/>This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as &#8220;predicts,&#8221; &#8220;believes,&#8221; &#8220;potential,&#8221; &#8220;proposed,&#8221; &#8220;continue,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should&#8221; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the timing and ability to initiate the IGNITE trial; the ability of ALLO-605 and TurboCARs to control T cell exhaustion, improve T cell function, improve potency, and reduce dosing requirements of AlloCAR T\u2122\u00a0cells; the ability to manufacture AlloCAR T\u2122 therapies; and the potential benefits of AlloCAR T therapies. Various factors may cause differences between Allogene\u2019s expectations and actual results as discussed in greater detail in Allogene\u2019s filings with the SEC, including without limitation in its Form 10-K for the year ended December 31, 2020. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.<\/p>\n<p>AlloCAR T\u2122 and TurboCAR\u2122 are trademarks of Allogene Therapeutics, Inc.<\/p>\n<p>ALLO-605 utilizes TALEN\u00ae gene-editing technology pioneered and owned by Cellectis. Allogene has an exclusive license to the Cellectis technology for allogeneic products directed at BCMA and holds all global development and commercial rights for this investigational candidate.<\/p>\n<p>\n        <strong>Allogene Media\/Investor Contact:<\/strong><br \/>\n        <br \/>Christine Cassiano<br \/>Chief Communications Officer<br \/>(714) 552-0326<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rwSRS5l_dOsVbqZyJIUsWHmSvPtfV1K_RqznOpUbw5sVGN92zp1UgNXbf7Jw6WtNXa4d0SFi5S9rUa2KiH_XzPF8i6qPqS5ZUlNCB3O_vOki91ayE6uf3WRngOomwF_K\" rel=\"nofollow noopener\" target=\"_blank\">Christine.Cassiano@allogene.com<\/a><\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxODkyOCM0MTI2Mzk1IzIxMjQyNDc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/0ad77463-dfa5-4173-b5d6-c525be98ca4d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>TurboCAR Technology Allows a Programmable Cytokine Signaling to Potentially Control T Cell Exhaustion and Improve Function and Potency of AlloCAR T\u2122\u00a0Cells Phase 1 IGNITE Trial Expected to Begin in Mid-2021 ALLO-605 is One of Allogene\u2019s Three Strategies to Target BCMA for the Treatment of Patients with Multiple Myeloma SOUTH SAN FRANCISCO, Calif., April 19, 2021 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) therapies for cancer today announced that the\u00a0U.S. Food &amp; Drug Administration\u00a0(FDA) has cleared an Investigational New Drug (IND) application to study ALLO-605 for the treatment of patients with relapsed or refractory multiple myeloma. ALLO-605 is part of the company\u2019s multi-faceted strategy to develop an &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR\u2122 Candidate, for the Treatment of Patients with Relapsed\/Refractory Multiple Myeloma&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-477996","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR\u2122 Candidate, for the Treatment of Patients with Relapsed\/Refractory Multiple Myeloma - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR\u2122 Candidate, for the Treatment of Patients with Relapsed\/Refractory Multiple Myeloma - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"TurboCAR Technology Allows a Programmable Cytokine Signaling to Potentially Control T Cell Exhaustion and Improve Function and Potency of AlloCAR T\u2122\u00a0Cells Phase 1 IGNITE Trial Expected to Begin in Mid-2021 ALLO-605 is One of Allogene\u2019s Three Strategies to Target BCMA for the Treatment of Patients with Multiple Myeloma SOUTH SAN FRANCISCO, Calif., April 19, 2021 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) therapies for cancer today announced that the\u00a0U.S. Food &amp; Drug Administration\u00a0(FDA) has cleared an Investigational New Drug (IND) application to study ALLO-605 for the treatment of patients with relapsed or refractory multiple myeloma. ALLO-605 is part of the company\u2019s multi-faceted strategy to develop an &hellip; Continue reading &quot;Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR\u2122 Candidate, for the Treatment of Patients with Relapsed\/Refractory Multiple Myeloma&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-19T12:33:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxODkyOCM0MTI2Mzk1IzIxMjQyNDc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR\u2122 Candidate, for the Treatment of Patients with Relapsed\\\/Refractory Multiple Myeloma\",\"datePublished\":\"2021-04-19T12:33:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\\\/\"},\"wordCount\":803,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxODkyOCM0MTI2Mzk1IzIxMjQyNDc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\\\/\",\"name\":\"Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR\u2122 Candidate, for the Treatment of Patients with Relapsed\\\/Refractory Multiple Myeloma - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxODkyOCM0MTI2Mzk1IzIxMjQyNDc=\",\"datePublished\":\"2021-04-19T12:33:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxODkyOCM0MTI2Mzk1IzIxMjQyNDc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxODkyOCM0MTI2Mzk1IzIxMjQyNDc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR\u2122 Candidate, for the Treatment of Patients with Relapsed\\\/Refractory Multiple Myeloma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR\u2122 Candidate, for the Treatment of Patients with Relapsed\/Refractory Multiple Myeloma - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/","og_locale":"en_US","og_type":"article","og_title":"Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR\u2122 Candidate, for the Treatment of Patients with Relapsed\/Refractory Multiple Myeloma - Market Newsdesk","og_description":"TurboCAR Technology Allows a Programmable Cytokine Signaling to Potentially Control T Cell Exhaustion and Improve Function and Potency of AlloCAR T\u2122\u00a0Cells Phase 1 IGNITE Trial Expected to Begin in Mid-2021 ALLO-605 is One of Allogene\u2019s Three Strategies to Target BCMA for the Treatment of Patients with Multiple Myeloma SOUTH SAN FRANCISCO, Calif., April 19, 2021 (GLOBE NEWSWIRE) &#8212; Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T\u2122) therapies for cancer today announced that the\u00a0U.S. Food &amp; Drug Administration\u00a0(FDA) has cleared an Investigational New Drug (IND) application to study ALLO-605 for the treatment of patients with relapsed or refractory multiple myeloma. ALLO-605 is part of the company\u2019s multi-faceted strategy to develop an &hellip; Continue reading \"Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR\u2122 Candidate, for the Treatment of Patients with Relapsed\/Refractory Multiple Myeloma\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-19T12:33:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxODkyOCM0MTI2Mzk1IzIxMjQyNDc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR\u2122 Candidate, for the Treatment of Patients with Relapsed\/Refractory Multiple Myeloma","datePublished":"2021-04-19T12:33:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/"},"wordCount":803,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxODkyOCM0MTI2Mzk1IzIxMjQyNDc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/","name":"Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR\u2122 Candidate, for the Treatment of Patients with Relapsed\/Refractory Multiple Myeloma - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxODkyOCM0MTI2Mzk1IzIxMjQyNDc=","datePublished":"2021-04-19T12:33:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxODkyOCM0MTI2Mzk1IzIxMjQyNDc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxODkyOCM0MTI2Mzk1IzIxMjQyNDc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/allogene-therapeutics-receives-ind-clearance-from-the-u-s-food-and-drug-administration-for-allo-605-the-first-turbocar-candidate-for-the-treatment-of-patients-with-relapsed-refractory-mult\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Allogene Therapeutics Receives IND Clearance from the U.S. Food and Drug Administration for ALLO-605, the First TurboCAR\u2122 Candidate, for the Treatment of Patients with Relapsed\/Refractory Multiple Myeloma"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/477996","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=477996"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/477996\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=477996"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=477996"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=477996"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}